Dr. Jennifer Derebery joins Strategic Pharmaceutical Advisors

PRLog (Press Release) – Aug 27, 2008 – Strategic Pharmaceutical Advisors (SRxA), a leading U.S. healthcare strategic marketing consulting and education firm, proudly announces the addition of M. Jennifer Derebery, MD as Vice President of Strategic Ear, Nose & Throat.  

A recognized expert in allergy and otologist conditions, Dr. Derebery became the first and only woman President of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) serving for the 2003-2004 term.  She is in private practice at the House Clinic in Los Angeles, CA, where she specializes in the diagnosis and treatment of allergy-related hearing loss and associated disorders.  She serves on the medical board of the House Ear Institute, and is a Clinical Professor of Otolaryngology at the Keck School of Medicine, University of Southern California, Los Angeles.

Dr. Derebery received her medical degree from the University of Texas Medical Branch in Galveston.  She then completed an Otolaryngology residency at  the Oregon Health Sciences University in Portland, OR, and an allergy fellowship sponsored by the American Academy of Otolaryngic Allergy in Kansas City, MO.  She is the author and co-author of numerous papers on topics of otolaryngology and allergy, particularly as related to otologic conditions.  Dr. Derebery is listed in the Guide to Best Doctors in America, Marquis Who’s Who, and is the recipient of numerous awards for her clinical and research studies.

Strategic Ear, Nose & Throat Advisors (SENTA) is a network of experts in otolaryngology.   Michael S. Benninger, MD, Executive Vice President and Medical Director of SENTA, warmly welcomed her commenting “Dr. Derebery is recognized for her innovation and know-how in analyzing and solving  clinical problems. Her addition to the team will help our clients reach the pinnacle of knowledge and health care management in otolaryngology.”  In addition to Drs. Derebery and Benninger, the team of experts includes James A. Hadley, MD, and Bradley F. Marple, MD.

“Since its inception, SRxA has successfully assisted pharmaceutical and medical device companies with innovative educational, clinical, regulatory, and marketing support programs with the utmost degree of scientific integrity. Dr. Derebery’s addition to our team further strengthens our services and our ability to address the needs of our clients worldwide” said Christos Efessiou, SRxA’s Chief Executive Officer.  

SRxA operates on a unique business model that utilizes clinical teams of national and international experts who partner with experts in industry and communications to provide the latest information and education in allergy, asthma, immunology, pulmonary diseases, and otolaryngology.  

In addition to SENTA, other clinically focused SRxA affiliates include Strategic Allergy Advisors (SAA) Strategic Pulmonary Advisors (SPA), and Strategic Respiratory Advisors – Europe. The company plans to introduce new affiliates in other key specialties in the near future.  

SRxA is headquartered in Washington, DC with offices in London and Hong Kong.  For more information please visit our www.srxa.com